Alexandria Real Estate Equities Investors Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Class Action Notice: The Portnoy Law Firm advises Alexandria Real Estate Equities investors of a class action for those who purchased securities between January 27, 2025, and October 27, 2025, with a deadline for lead plaintiff motions set for January 26, 2026, emphasizing the urgency for affected investors to act.
- Disappointing Financial Results: Alexandria reported below-expectation financial results for Q3 FY2025, notably cutting its full-year funds from operations (FFO) guidance, indicating significant operational challenges faced by the company.
- Impairment Charge Impact: The company faced a $323.9 million impairment charge, primarily due to lower occupancy rates and slower leasing activity, with $206 million attributed to its Long Island City property, leading to a 19.17% drop in stock price to $62.94 per share on October 28, 2025, reflecting market concerns about its future.
- Legal Support and Consultation: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to discuss their legal options for recovering losses, demonstrating a commitment to protecting investor rights and providing necessary support.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 59.690
Low
15.84
Averages
51.53
High
67.00
Current: 59.690
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
